Owlstone Medical selected as finalist in IPF Catalyst Challenge
Owlstone Medical have been chosen as finalists in a competition for $1 million of funding for life-changing research into Idiopathic Pulmonary Fibrosis (IPF).
Owlstone Medical’s Breath Biopsy Platform integrated into GSK’s clinical trial
Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced that GSK, a world leader in respiratory, will incorporate Owlstone Medical’s Breath Biopsy platform into the clinical development programme of danirixin, one of the novel drug candidates in its respiratory disease pipeline.
See Owlstone Medical's ReCIVA Breath Sampler at London's Science Museum
Owlstone Medical's ReCIVA Breath Sampler is being featured at London's Science Museum. ReCIVA will be on display in the Tomorrow's World Gallery until the end of December 2017. Entry to the exhibition is free.
Pan cancer clinical trial aims to evaluate breath biopsy for early detection of disease
Scientists in Cambridge are to run a PAN cancer clinical trial to see if breath samples can be used to detect cancer in its early stages, the Cancer Research UK (CRUK) Cambridge Centre and Owlstone Medical have announced.
Owlstone Medical CEO Billy Boyle wins Royal Academy of Engineering’s Silver Medal
Billy Boyle, Founder and CEO of Owlstone Medical, a diagnostics company developing a breathalyzer for disease, is to be awarded the Royal Academy of Engineering’s prestigious Silver Medal. The award recognizes engineer Billy’s work in spearheading the development of the company’s Breath Biopsy platform and driving a vision to save 100,000 lives and $1.5 billion in healthcare costs.
Owlstone Medical appoints Professor Sir Bruce Ponder to new Scientific Advisory Board
Owlstone Medical, a diagnostics company developing a breathalyzer for disease, announced today the appointment of Professor Sir Bruce Ponder FRCP FMedSci FRS to its newly established Scientific Advisory Board (SAB) with immediate effect.
Owlstone Medical and Mayo Clinic collaborate to improve effectiveness of colonoscopy
Owlstone Medical, a diagnostics company developing a breathalyzer for disease, today announced it has entered into collaboration with Mayo Clinic, the leading US non-profit medical practice, education, and medical research group. The company’s FAIMS technology is being used in a clinical trial to evaluate its performance as a rapid, point-of-care test to non-invasively assess the adequacy of…
Aviva Invests in Owlstone medical breath biopsy platform
Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, has announced an investment from Aviva Ventures, the venture capital arm of Aviva plc, a global leader in insurance. The investment takes Owlstone Medical’s total funding to £19.3 million GBP ($23.5 million USD) since its spin-out from Owlstone Inc in 2016.
Owlstone Medical opens new high volume breath biopsy lab with Tony Blair visit
Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today welcomed former Prime Minister Tony Blair to its headquarters in Cambridge, where he officially opened the company’s new high volume clinical laboratory.
Owlstone Medical to provide Breath Biomarker Services for 4D Pharma
A partnership between Owlstone Medical and 4D Pharma plc aims to identify non-invasive VOC biomarkers in the development of live biotherapeutics for disease diagnosis and patient stratification.
Owlstone Medical begins 1,400 patient clinical trial for early detection of colorectal cancer
The world’s largest breath-based study into colorectal (bowel) cancer will be run in collaboration with the University of Warwick and the University Hospital Coventry and Warwickshire NHS Trust.
Owlstone Medical announces £9.3M fundraising
Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced that it has successfully raised £9.3 million ($11.55 million USD) financing. The investment round was led by existing investors, and will be used to commercially launch the company’s breath biomarker R&D services, including the opening of a new high volume clinical facility, and to fund ongoing…
Owlstone Medical’s ReCIVA named 'Invention of the year' in Top 50 Digital Health Awards
Owlstone Medical, a diagnostics company developing a breathalyzer for disease, announced today that its ReCIVA breath sampling and analysis technology has been named Invention of the Year in the 2017 Top 50 in Digital Health Awards.
Owlstone Medical and Imperial College to study underlying causes of asthma exacerbations
Owlstone Medical, a diagnostics company, today announced it has entered into collaboration with Imperial College London, the world leading science-based research institution and university. The company’s breath analysis technology will be deployed in an ongoing study led by Imperial College to evaluate underlying causes of exacerbations in severe asthma patients.
Owlstone Medical receives CE mark approval for pediatric disease breathalyzer
Extends ReCIVA technology deployment in MRC EMBER project for use in acutely breathless children and asthmatics
Owlstone Medical begins next phase in breath-based clinical trial for early cancer detection
Owlstone Medical, a diagnostics company, has announced that it is expanding its Lung Cancer Indicator Detection (LuCID) clinical trial. The study, originally funded by the Small Business Research Initiative for Healthcare (SBRI Healthcare), an NHS England funded initiative, aims to save 10,000 lives and save the NHS £245 million by 2020 with a quick, easy to use, non-invasive, high-compliance…
Owlstone Medical strengthens management team
Chris Hodkinson, Dr Marc van der Schee and Hamilton Scanlon join the company
Owlstone Medical closes $7M (£4.9M) investment to commercialise disease breathalyzer
Owlstone Medical Ltd, a diagnostics company, has been spun out of parent company, Owlstone Inc, to develop and commercialise a breathalyzer for use in clinical diagnostics and precision medicine with applications in cancer, inflammatory and infectious disease. Based in Cambridge, UK, the Company announced today that it has successfully raised $7 million (£4.9 million) financing.
Owlstone opens new manufacturing facility on Cambridge Science Park
Labour Parliamentary Candidate Daniel Zeichner cut the ribbon last week on Owlstone's new manufacturing facility on the Cambridge Science Park. The new building will accommodate increased orders and an expanding workforce.
Owlstone introduces UltraFAIMS for improved mass spectrometry
Owlstone introduces a low-cost accessory for mass spectrometers that provides an additional dimension of high-speed separation by ion mobility.